Portal de Periódicos da CAPES

Prevention of restenosis by a novel drug-eluting stent system with a dose-adjustable, polymer-free, on-site stent coating

2005; Oxford University Press; Volume: 26; Issue: 15 Linguagem: Inglês

10.1093/eurheartj/ehi405

1522-9645

Jörg Hausleiter, Adnan Kastrati, Rainer Wessely, Alban Dibra, Julinda Mehilli, Thomas Schratzenstaller, Isolde Graf, Magdalena Renke-Gluszko, Boris Behnisch, Josef Dirschinger, Erich Wintermantel, Albert Schömig,

Cardiac Valve Diseases and Treatments

Aims Drug-eluting stents (DES) represent a major advance in interventional cardiology. Along with the success shown, current DES also present limitations related to the presence of polymer-coating, fixed drug, and dose used. With the ISAR (Individualized Drug-Eluting Stent System to Abrogate Restenosis) project, a DES system has been developed that permits individualized choice of the drug and dose to use for the given patient. The objective of this prospective dose finding study was to assess the feasibility, safety, and efficacy of a polymer-free on-site stent coating with increasing rapamycin doses.